CD8A and neoplasm: The number of MDSCs in TME, lymph nodes, and spleens decreased by 20, 0.8, and 35% after the combination of cabozantinib and anti‐HER2 mAb. the combined treatment also inhibited the Arg 1 expression on MDSCs and recruited CD8+T cells into tumor site, tumor‐draining lymph nodes, and splenic lymphocytes